Projet META-CAN (Horizon 2020, appel à projets 2017)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

Cancer cells show common features of profound metabolic changes and escape from the immune system, independently of their tissue of origin. These metabolic adaptations are not limited to glucose metabolism (the "Warburg effect") but are more general and affect several metabolic pathways in cancer cells as well as in the stroma, including immune cells. This network will explore how nutrients and hypoxia regulate the tumor-immune system interplay, and how this communication is controlled by oncogenes, metabolic regulators and current or potential drugs targeting metabolism. Understanding how metabolism can affect tumor cells and the anti-cancer immune response represents a potential therapeutic intervention point that can be exploited to develop novel therapies and new diagnostic and prognostic markers. The development of therapies targeting cancer metabolism is hampered by: 1) the complexity of the regulation that metabolism exerts on many different tumor layers, which requires multidisciplinary collaborations, and 2) the shortage of scientists that can navigate with ease between academic, industrial and clinical sectors and have the scientific and complementary skills to convert research findings into commercial and clinical applications. This network provides a pan-European interdisciplinary and intersectoral training program of excellence bringing young researchers together with World leading academics, clinicians, pharma industry members, corporate research and dissemination and outreach specialists. As part of the research training, the consortium will conduct a coherent and integrated set of hypothesis-driven research projects that are aimed at discovering, describing and exploiting how metabolism at the cell and the whole body levels is integrated with modulation of cell death susceptibility and the immune response in the context of cancer.

Mots clés : cancer metabolism, cancer immunology, immunometabolism, cell death

Participants :
- Medical University of Vienna (Autriche) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 511868.16 €
- Ramon Llull University (Espagne) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Technion – Israel Institute of Technology (Israël) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Technion – Israel Institute of Technology (Israël) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 455525.91 €
- Canceropôle Provence - Alpes - Côte-d'Azur (France) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Amsterdam University Medical Centers (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Amsterdam University Medical Centers (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 255374.28 €
- Boehringer Ingelheim (Austria) (Autriche) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Institut d'Investigació Biomédica de Bellvitge (Espagne) — Coordinator, beneficiary, Recherche, subvention : 743618.88 €
- Université Paris Cité (France) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 262875.6 €
- Institut national de la santé et de la recherche médicale (France) — Partner, beneficiary, Recherche, subvention : 525751.2 €
- Agilent Technologies (United States) (Etats-Unis) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Vlaams Instituut voor Biotechnologie (Belgique) — Partner, beneficiary, Recherche, subvention : 501120.0 €
- Evotec (france) sas (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 262875.6 €
- The febs journal (febs) (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Hospital Sant Joan de Déu Barcelona (Espagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Biocomunicat (Espagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- IBM Research - Haifa (Israël) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 65075.13 €
- Applied Research Using OMIC Sciences (Spain) (Espagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 247872.96 €
- Assistance publique - Hôpitaux de Paris (France) — Partner, beneficiary, Recherche, subvention : 0.0 €